Nuvig Therapeutics is a technology company.
Nuvig Therapeutics has raised $160.0M across 1 funding round.
Nuvig Therapeutics has raised $160.0M in total across 1 funding round.
Nuvig Therapeutics has raised $160.0M in total across 1 funding round.
Nuvig Therapeutics's investors include Catalio Capital, MPM Capital, Polaris Partners.
Nuvig Therapeutics is a clinical-stage biotechnology company developing novel immune therapeutics for chronic inflammatory and autoimmune diseases, focusing on non-immunosuppressive treatments that restore immune homeostasis.[1][2][3][5] Its lead product, NVG-2089, is a recombinant Fc fragment engineered to mimic the anti-inflammatory effects of intravenous immunoglobulin (IVIG) but with 10- to 20-fold greater potency, enabling shorter infusions while targeting conditions like chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), and dermatological disorders.[2][5][6][7] Nuvig serves patients with severe autoimmune diseases where current options are limited by immunosuppression risks or IVIG's logistical challenges, addressing unmet needs through its BESTech™ platform that enhances validated drug targets.[1][5][7] The company has shown strong growth, raising $47 million in Series A (2022) and $161 million in Series B financing to advance Phase 2 trials.[3][5]
Nuvig Therapeutics was co-founded in 2021 by Pamela Conley, PhD (experienced biotech executive with over 30 years, former VP of Biology at Portola Pharmaceuticals), Greg Coffey, PhD, and led clinically by Alan Glicklich, MD, building on research from Dr. Jeffrey Ravetch’s lab at The Rockefeller University.[2][6] Conley licensed and expanded this technology from Ravetch’s work while at Portola (acquired for $1.4B in 2020), distilling IVIG's active anti-inflammatory components into engineered Fc fragments.[2][6] The company emerged from stealth in May 2022 with $47M Series A funding led by Novo Holdings and others, quickly achieving first-in-human dosing for NVG-2089 and progressing to Phase 2.[2][3] Early preclinical data in animal models validated superior potency, setting the stage for clinical traction.[2]
Nuvig stands out in autoimmune therapy through its precise, mechanism-driven approach:
Nuvig rides the autoimmune disease treatment revolution, targeting a market affecting millions with limited safe options amid rising prevalence of conditions like CIDP and ITP.[3] Its timing aligns with advances in immune modulation (paralleling FcRn antagonists like argenx, valued over $30B), emphasizing homeostasis over suppression amid post-pandemic focus on infection-safe therapies.[3][6] Favorable forces include surging biotech investment in immunology, validated IVIG mechanisms, and demand for potent, scalable alternatives to plasma-derived drugs.[2][5] Nuvig influences the ecosystem by pioneering Fc engineering, potentially upgrading pipelines via partnerships and expanding non-immunosuppressive standards.[2][5]
Nuvig is poised for Phase 2 readouts in CIDP and ITP by 2026, with preclinical BESTech™ combos opening partnering deals and pipeline growth into neurology/dermatology.[2][5][7] Trends like precision immunomodulation and AI-driven drug design will accelerate its validation, while regulatory emphasis on novel mechanisms favors its profile. As autoimmune therapies evolve toward homeostasis, Nuvig could redefine standards like IVIG did, delivering transformative options without compromise—positioning it as a biotech leader from its scientifically-driven origins.[1][6]
Nuvig Therapeutics has raised $160.0M across 1 funding round. Most recently, it raised $160.0M Series B in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $160.0M Series B | Catalio Capital, MPM Capital, Polaris Partners |